Superworth

Denali Therapeutics revenue DNLI

Sales by quarter and over the last twelve months, from 2017.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$3.6M
Fiscal year 2024
$0
−100% on the year before

Denali Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $3.6M.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$0−100%
FY2023$330.5M+205%
FY2022$108.5M+123%
FY2021$48.7M−86%
FY2020$335.7M+1158%
FY2019$26.7M−79%
FY2018$129.2Mn/a
FY2017$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$3.6Mn/an/a
Q2 FY25$0n/an/a
Q4 FY24$0n/a$0
Q3 FY24$0−100%$0
Q2 FY24$0−100%$1.3M
Q1 FY24$0−100%$295.4M
Q4 FY23$0−100%$330.5M
Q3 FY23$1.3M−64%$340.8M
Q2 FY23$294.1M+460%$343.1M
Q1 FY23$35.1M−17%$101.5M
Q4 FY22$10.3M−18%$108.5M
Q3 FY22$3.6M−33%$110.7M

Against its peers

Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
DNLIDenali Therapeuticsn/m
ADMAAdma Biologics$512.3M+8% a year
VCELVericel$306.3M+23% a year
KRYSKrystal Biotech$440.5M+23% a year
MGTXMeiraGTx$397.5M
RGENRepligen$785.1M+16% a year
TECHBIO-TECHNE$1.2B−0% a year
HALOHalozyme Therapeutics$1.7B+41% a year
NBIXNeurocrine Biosciences$3.4B+34% a year
EXELExelixis$2.4B+9% a year
INCYIncyte$5.8B+27% a year
Peer median$1B

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Denali Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.